Literature DB >> 33653205

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study.

Joaquín Martínez-López1, Satu Mustjoki2,3, Kimmo Porkka3, Rebecca B Klisovic4, Dominik Wolf5,6, Lambert Busque7,8, Juan Carlos Hernández-Boluda9, Rene Swanink10, Patricia Martin Regueira10, Jeffrey H Lipton11.   

Abstract

Entities:  

Year:  2021        PMID： 33653205     DOI： 10.1080/10428194.2021.1889536

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.

Authors:  Jonathan A Webster; Tara M Robinson; Amanda L Blackford; Erica Warlick; Anna Ferguson; Ivan Borrello; Marianna Zahurak; Richard J Jones; B Douglas Smith
Journal:  Leuk Res       Date:  2021-11-02       Impact factor: 3.156

2.  Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.

Authors:  Patrick Harrington; Richard Dillon; Deepti Radia; Donal McLornan; Claire Woodley; Susan Asirvatham; Kavita Raj; Natalia Curto-Garcia; Jamie Saunders; Shahram Kordasti; Claire Harrison; Hugues de Lavallade
Journal:  Br J Haematol       Date:  2022-07-08       Impact factor: 8.615
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.